ClinicalTrials.gg
RecruitingNCT07132567Updated Nov 3, 2026

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

An observational study in Mycosis Fungoides and Sezary Syndrome, sponsored by Kyowa Kirin Co., Ltd.. Recruiting at 6 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Kyowa Kirin Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 3, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
15
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.

Read the detailed description

This post-marketing surveillance (PMS) is designed as an all-case investigation in accordance with the Korean Ministry of Food and Drug Safety (MFDS) re-examination requirements. It targets adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy and are treated with mogamulizumab (POTELIGEO® Injection 20 mg) under the approved indication in Korea.

Primary Objective: To assess the safety of mogamulizumab for patients treated under the approved indication in Korea.

Secondary Objective: To assess the effectiveness of mogamulizumab for patients treated under the approved indication in Korea.

Exploratory Objective: To perform additional subgroup and exploratory analyses of effectiveness, including evaluation in special populations such as elderly patients, patients with renal or hepatic impairment, and those with a history of hematopoietic stem cell transplantation, treated under the approved indication in Korea

02

Conditions studied

  • Mycosis Fungoides
  • Sezary Syndrome

Keywords

  • Poteligeo
  • mycosis fungoides
  • Sezary syndrome
03

In context

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

This study's planned enrollment of 15 is below the median of 100 across 51 observational studies indexed under Mycosis Fungoides.

Browse Mycosis Fungoides studies →

Lead sponsor

Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A person who has Mycosis fungoides and sezary syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults 19 years of age or older
  2. Individuals who are confirmed to have received administration of the study drug for the purpose of "the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies," or who are considered to require administration of the study drug in the investigator's opinion
  3. Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance

Exclusion criteria

Exclusion Criteria

  1. Patients with to any ingredients of this drug
  2. Patients who intend to use this drug for non-approved indications
  3. Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Interventions

06

What researchers measure

Primary outcomes

  1. Safety (Special situation, adverse event, symptom, or disease occurring during treatment with Poteligeo)

    Number of participants who experience any adverse event or special situation during Poteligeo treatment and up to 90 days after the last dose, as recorded in CRFs based on medical examinations or spontaneous reports.

    Time frame: From first administration of Poteligeo through 90 days after the last dose

Secondary outcomes

  1. Change from baseline to after 8th administration in Global Response Score (GRS)

    Change in Global Response Score (GRS) from baseline (before first dose) to after the 8th administration, assessing skin, nodes, blood, and viscera. CR/PR = Effective; SD/PD/Relapse = Ineffective.

    Time frame: Baseline (Day 1, prior to first dose) and Week 24 (after completion of 8th administration)

07

Study locations

5 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Sep 2028, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 20, 2025
StartActual
May 2, 2025
Primary completionEst.
Sep 2028
CompletionEst.
Nov 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: h•••@kyowakirin.com · •••3471→h•••@kyowakirin.com · •••3471. See the current contact
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Contact Study contact changed: h•••@kyowakirin.com · •••3471→h•••@kyowakirin.com · •••3471. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07132567
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
May 2, 2025
Primary completion
Sep 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Hyejin Noh
Contact
hyejin.noh.2u@kyowakirin.com
+82-10-3378-3471
Hyejin Noh
study director · Kyowa Kirin Korea Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion